Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Oliver KleinJonathan Cebon

Abstract

Combination immunotherapy with anti-CTLA-4 and anti-PD-1 blockade has demonstrated significant clinical activity across several tumor types. Neuroendocrine tumors (NET) are a heterogeneous group of rare tumors with limited treatment options. CA209-538 is a clinical trial of combination immunotherapy with ipilimumab and nivolumab in rare cancers, including advanced NETs. CA209-538 is a prospective multicenter clinical trial in patients with advanced rare cancers. Patients received treatment with nivolumab at a dose of 3 mg/kg and ipilimumab at 1 mg/kg every three weeks for four doses, followed by nivolumab 3 mg/kg every two weeks and continued for up to 96 weeks, until disease progression or the development of unacceptable toxicity. Response was assessed every 12 weeks by RECIST 1.1. The primary endpoint was clinical benefit rate (CBR; complete remission + partial remission + stable disease). Twenty-nine patients with advanced NETs received treatment. Three (10%) patients had low-, 13 (45%) had intermediate-, and 13 (45%) had high-grade tumors; lung was the most common primary site (39%). The objective response rate was 24% with a CBR of 72%; 43% of patients with pancreatic neuroendocrine neoplasms (NEN), and 33% of patients wit...Continue Reading

References

Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoDouglas B Evans
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
Sep 13, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H SorbyeU Knigge
Jul 12, 2014·The New England Journal of Medicine·Martyn E CaplinUNKNOWN CLARINET Investigators
Dec 26, 2015·Lancet·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group
Jan 6, 2016·Neuroendocrinology·R Garcia-CarboneroUNKNOWN Vienna Consensus Conference participants
Jan 12, 2017·The New England Journal of Medicine·Jonathan StrosbergUNKNOWN NETTER-1 Trial Investigators
Sep 9, 2017·JAMA : the Journal of the American Medical Association·Suzanne L Topalian
Nov 2, 2017·Neoplasia : an International Journal for Oncology Research·Bryan OronskyCorey A Carter
Sep 29, 2019·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jan 24, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sandip P PatelRazelle Kurzrock
Jan 26, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jonathan StrosbergJulien Hadoux

❮ Previous
Next ❯

Citations

Dec 12, 2020·Expert Review of Anticancer Therapy·Jasna MetovicGiuseppe Pelosi
Dec 17, 2020·Human Vaccines & Immunotherapeutics·Arjun MittraAbdul Rafeh Naqash
Oct 20, 2020·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Eitan MirvisShaunak Navalkissoor
Feb 6, 2021·Endocrine·Anna KoumarianouKrystallenia I Alexandraki
Feb 10, 2021·Current Treatment Options in Oncology·Nicola Fazio, Omar Abdel-Rahman
Nov 19, 2020·Journal of Clinical Medicine·Mauro CivesJonathan Strosberg
Apr 15, 2021·Reviews in Endocrine & Metabolic Disorders·Manuela AlbertelliDiego Ferone
Apr 22, 2021·American Journal of Clinical Oncology·Wei YangXiaofeng Xu
May 1, 2021·Cancers·Anna La SalviaRocío Garcia-Carbonero
May 27, 2021·Japanese Journal of Clinical Oncology·Susumu HijiokaJunji Furuse
Jun 11, 2021·Current Treatment Options in Oncology·Kazhan MollazadeganJoakim Crona
Jun 30, 2021·Current Treatment Options in Oncology·Mohammed DawodAngela Lamarca
Aug 3, 2021·Journal of the National Comprehensive Cancer Network : JNCCN·Manisha H ShahCindy Hochstetler
Aug 4, 2021·Journal of Neuroendocrinology·Jain PranteshAmr Mohamed
Sep 3, 2021·Cancer Immunology, Immunotherapy : CII·Christo KoleDimitrios Schizas
Oct 21, 2021·Annual Review of Medicine·Amy ChangVaibhav Sahai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.